Publication details
Přehled přínosu daratumumabu pro léčbu všech monoklonálních gamapatií, ale i dalších nemocí a vlastní zkušenosti s léčbou 74 pacientů daratumumabem, lenalidomidem a dexametazonem
| Title in English | Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Onkologie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.onkologiecs.cz/artkey/xon-202288-0005_prehled_prinosu_daratumumabu_pro_lecbu_vsech_monoklonalnich_gamapatii_ale_i_dalsich_nemoci_a_vlastni_zkusenost.php |
| Doi | http://dx.doi.org/10.36290/xon.2022.057 |
| Keywords | daratumumab; mechanism of action; multiple myeloma; monoclonal gammopathy of clinical signifikance; AL-amyloidosis |
| Description | Multiple myeloma (MM) is a hematological malignancy characterized by renal insufficiency, bone lesions, anaemia, and hypercalcemia. In this modern era of medicine, even with the development of drugs like immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI), the treatment of MM prevails as a challenge. However, even after the attainment of total remission, relapse of MM and disease progression is frequent. That is why there is an urgent requirement to develop novel monoclonal antibody drugs. The latest drugs for the treatment of relapsed and refractory MM (RRMM) approved by the Food and Drug Administration (FDA) is daratumumab. In this article, we will discuss daratumumab with different combination therapies in multiple myeloma, but also in other indications. Information about the efficacy in various type of Monoclonal Gammopathy of Clinical Significance are reviewed. Several studies tested daratumumab in autoimmune diseases with positive results. The goal of this publication is to give information about all indication in which daratumumab was tested with positive results. And we alsou inform about our own experiencies with daratumumab, lenalidomide dexamethasone in 74 pacients treated in the year 2018-2021. |